Narrative review / 2010
After 33 years and at least 1,591 patients, it remains unknown whether vitamin C has clinically significant antitumor activity.
This review evaluates 33 years of clinical trials involving at least 1,591 cancer patients treated with vitamin C. A 1976 study reporting that 100 terminal cancer patients given intravenous and oral vitamin C lived four times longer than 1,000 controls was strongly criticized for major control group imbalances that artificially extended survival. Subsequent trials, including three double-blind placebo-controlled randomized trials of oral vitamin C at the Mayo Clinic, were negative, and a phase I-II trial of intravenous vitamin C found zero responses in 24 patients. The authors conclude it is still unknown whether vitamin C has any clinically significant antitumor activity, which cancer types might be susceptible, or what dose might produce a therapeutic response.
- Study type
- Narrative review
- Who was studied
- At least 1,591 cancer patients across 33 years of trials
- What was measured
- Survival, tumor shrinkage, and antitumor response
THE PAPER
Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?
Cabanillas F. P R Health Sci J, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.